Abbott Laboratories news

   Watch this stock
Showing stories 1 - 10 of about 122   

Articles published

ABT 42.46 +0.03 (0.07%)
price chart
Abbott Laboratories Q3 Earnings: Global Sales Up 5.6%
Abbott Laboratories saw its third-quarter revenue rise 5.8 percent, to $5.1 billion, thanks to strong sales of branded pharmaceuticals and nutrition goods, along with a boost in its vision care products.
Mylan revises terms of Abbott Labs deal  Pittsburgh Post Gazette
Abbott Laboratories (ABT) Earnings Report: Q3 2014 Conference Call Transcript  TheStreet.com
Related articles »  
Today's Unusual Social Activity Stock: Abbott Laboratories (ABT)
Abbott Laboratories manufactures and sells health care products worldwide. The stock currently has a dividend yield of 2.1%.
Abbott Laboratories Tops Earnings Estimates
Abbott Laboratories (NYSE:ABT) released the earnings results from its third quarter before opening bell this morning, posting adjusted earnings of 62 cents per share, a 12.7% growth rate, on $5.1 billion in revenue.
Abbott Laboratories ABT Announces Acquisition of CFR Pharmaceuticals
ABBOTT PARK, Ill., Sept. 26, 2014 - Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets.
Company Update: Abbott Laboratories (NYSE:ABT) - Abbott Completes ...  Jutia Group
Abbott Labs Acquires Control Of CFR Pharma - Quick Facts  RTT News
Related articles »  
Abbott Laboratories' EPS Up 12% On Emerging Market Strength
Abbott Laboratories (NYSE:ABT) is a large cap ($64 billion market cap) diversified health care provider. The company has paid increasing dividend payments for 42 consecutive years.
Abbott Laboratories: Analysis Of Q3 Earnings Miss (ABT)
Abbott Laboratories just reported its preliminary financial results based on which we provide a unique corporate earnings release based analysis of its performance.
Abbott Labs (ABT) Earnings Up Y/Y in Q3, Guidance Updated
We note that Abbott Labs agreed to sell its developed markets generics pharmaceutical business to Mylan (MYL - Analyst Report) in Jul 2015.
Abbott-Mylan Tax Inversion Deal In Spotlight
Abbott Laboratories (NYSE:ABT) and Mylan Inc (NASDAQ:MYL) announced today that the two companies still plan to go ahead with their $5.3 billion merger despite the announcement of new tax rules on September 22.
Abbott Laboratories Conference Call Highlights
Abbott Laboratories (NYSE: ABT) reported its third quarter earnings on Tuesday. Shares of the company are down 2 percent. Below are some key highlights from its conference call.
January 2017 Options Now Available For Abbott Laboratories (ABT)
Investors in Abbott Laboratories (NYSE: ABT) saw new options begin trading today, for the January 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 830 days until expiration ...
Related articles »